Macrophage-Specific NF-κB Activation Dynamics Can Segregate Inflammatory Bowel Disease Patients
Overview
Authors
Affiliations
The heterogeneous nature of inflammatory bowel disease (IBD) presents challenges, particularly when choosing therapy. Activation of the NF-κB transcription factor is a highly regulated, dynamic event in IBD pathogenesis. Using a lentivirus approach, NF-κB-regulated luciferase was expressed in patient macrophages, isolated from frozen peripheral blood mononuclear cell samples. Following activation, samples could be segregated into three clusters based on the NF-κB-regulated luciferase response. The ulcerative colitis (UC) samples appeared only in the hypo-responsive Cluster 1, and in Cluster 2. Conversely, Crohn's disease (CD) patients appeared in all Clusters with their percentage being higher in the hyper-responsive Cluster 3. A positive correlation was seen between NF-κB-induced luciferase activity and the concentrations of cytokines released into medium from stimulated macrophages, but not with serum or biopsy cytokine levels. Confocal imaging of lentivirally-expressed p65 activation revealed that a higher proportion of macrophages from CD patients responded to endotoxin lipid A compared to controls. In contrast, cells from UC patients exhibited a shorter duration of NF-κB p65 subunit nuclear localization compared to healthy controls, and CD donors. Analysis of macrophage cytokine responses and patient metadata revealed a strong correlation between CD patients who smoked and hyper-activation of p65. These dynamic assays of NF-κB activation in blood-derived macrophages have the potential to segregate IBD patients into groups with different phenotypes and may therefore help determine response to therapy.
A Novel Quinoline Inhibitor of the Canonical NF-κB Transcription Factor Pathway.
Ntavaroukas P, Michail K, Tsiakalidou R, Stampouloglou E, Tsiggene K, Komiotis D Biology (Basel). 2024; 13(11).
PMID: 39596865 PMC: 11591978. DOI: 10.3390/biology13110910.
Mandal M, Rakib A, Mamun M, Kumar S, Park F, Hwang D Biomed Pharmacother. 2024; 179:117379.
PMID: 39255739 PMC: 11479677. DOI: 10.1016/j.biopha.2024.117379.
Lee M, Chan B, Ng Y, Leung T, Shum T, Lou J Front Pharmacol. 2024; 15:1426803.
PMID: 39156108 PMC: 11327010. DOI: 10.3389/fphar.2024.1426803.
OBrien C, Summers K, Martin N, Carter-Cusack D, Yang Y, Barua R Hum Genet. 2024; 143(3):233-261.
PMID: 38421405 PMC: 11043138. DOI: 10.1007/s00439-024-02642-9.
Georgoula M, Ntavaroukas P, Androutsopoulou A, Xiromerisiou G, Kalala F, Speletas M Int J Mol Sci. 2024; 25(3).
PMID: 38339069 PMC: 10855941. DOI: 10.3390/ijms25031791.